Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PhoenixBio CoTSE:6190 -1.15%55 Days Inventory is 318.79 as of Mar. 2026, which is 69% above its 10-year median of 188.45. GuruFocus rates TSE:6190 with a GF Score™ of 55/100 and a GF Value™ of 円357.24 (Fairly Valued). The stock has 5 warning signs investors should review. Among 638 Biotechnology companies, PhoenixBio Co ranks worse than 70.85% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). PhoenixBio Co's Average Total Inventories for the
six
months ended in Mar. 2026 was 円321 Mil. PhoenixBio Co's Cost of Goods Sold for the
six
months ended in Mar. 2026 was 円183 Mil.
Hence, PhoenixBio Co's Days Inventory for the
six
months ended in Mar. 2026 was 318.79.
The historical rank and industry rank for PhoenixBio Co's Days Inventory or its related term are showing as below:
TSE:6190'
s Days Inventory Range Over the Past 10 Years
Min: 152.32 Med: 188.45 Max: 337.62
Current: 324.82
During the past 12 years, PhoenixBio Co's highest Days Inventory was 337.62. The lowest was 152.32. And the median was 188.45.
TSE:6190's Days Inventory is ranked worse than 70.85% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs TSE:6190: 324.82
PhoenixBio Co's Days Inventory
declined
from Mar. 2025 (381.16) to Mar. 2026 (318.79).
Inventory Turnover measures how fast the company turns over its inventory within a year.
PhoenixBio Co's Inventory Turnover for the
six
months ended in Mar. 2026 was 0.57.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
PhoenixBio Co's Inventory-to-Revenue for the
six
months ended in Mar. 2026 was 0.40.
PhoenixBio Co (TSE:6190) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
PhoenixBio Co's Inventory Turnover for the
six
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
PhoenixBio Co's Inventory to Revenue for the
six
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
PhoenixBio Co Days Inventory Related Terms
PhoenixBio Co Days Inventory Historical Data
* Premium members only.
The historical data trend for PhoenixBio Co's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6190 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, PhoenixBio Co's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhoenixBio Co Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PhoenixBio Co's Days Inventory distribution charts can be found below:
* The bar in red indicates where PhoenixBio Co's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhoenixBio Co (TSE:6190) has a Days Inventory of 318.79 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on PhoenixBio Co and its competitors. This is 69% above median its historical median of 188.45. Over the past decade, PhoenixBio Co's Days Inventory has ranged from 152.32 to 337.62. According to the industry distribution chart, PhoenixBio Co ranks #452 out of 638 companies in the Biotechnology industry, placing it in the top 70.8%.
Is PhoenixBio Co's Days Inventory too high?
PhoenixBio Co's current Days Inventory of 318.79 is 69% above median its 10-year median of 188.45. Over the past 10 years, this metric has ranged from a low of 152.32 to a high of 337.62. The Biotechnology industry median Days Inventory is 183.20. PhoenixBio Co's value of 318.79 is 74% above this industry median. Based on the distribution chart, PhoenixBio Co ranks #452 out of 638 companies in the Biotechnology industry, which is below the industry midpoint. Overall, PhoenixBio Co has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PhoenixBio Co's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PhoenixBio Co ranks #452 out of 638 companies for Days Inventory. This places PhoenixBio Co in the lower half of its industry. The industry median Days Inventory is 183.20. PhoenixBio Co's value of 318.79 is 74% above this benchmark. Historically, PhoenixBio Co's own Days Inventory has ranged from 152.32 to 337.62 over the past decade. While the company's 10-year median is 188.45 vs. the industry median of 183.20, PhoenixBio Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PhoenixBio Co's current Days Inventory of 318.79 is 74% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on PhoenixBio Co and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhoenixBio Co's current Days Inventory is 318.79, which is 69% above median its own 10-year median of 188.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhoenixBio Co stock overvalued right now?
Based on GuruFocus' analysis, PhoenixBio Co (TSE:6190) is currently considered Fairly Valued. The stock's GF Value™ is 円357.24, compared to a current price of 円343.00 — trading 4% below its estimated fair value. The current Days Inventory is 318.79, which is 69% above median its 10-year median of 188.45 and 74% above the Biotechnology industry median of 183.20. PhoenixBio Co's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For PhoenixBio Co (TSE:6190), the current Days Inventory is 318.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhoenixBio Co (TSE:6190) Overvalued in 2026?
Based on GuruFocus' analysis, PhoenixBio Co stock appears to be undervalued.
The current stock price of 円343.00 is trading 4% below its estimated GF Value™ of 円357.24.
GuruFocus considers PhoenixBio Co to be Fairly Valued.
Key valuation signals for TSE:6190:
Days Inventory: 318.79 (69% above median its 10-year median of 188.45)
GF Value™: 円357.24 vs. price of 円343.00 (4% below fair value)
Industry Position: 74% above the Biotechnology median (#452 of 638)
No single metric tells the full story. See the TSE:6190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics-related tests, safety tests, and hepatitis virus (HBV / HCV) related drug efficacy tests. Geographically, the company generates the majority of its revenue from USA.
55GF Score
Get the complete analysis for TSE:6190
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6190 has been successfully added to your 
